Patient Guide: An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID)

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 5 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT07076446
Status: 🟢 Enrolling Now
Condition: Primary Immunodeficiency
Phase: PHASE4

Where You Can Participate

This study is available at 5 locations across the country.

Top locations include:
  • • Litchfield Park, Arizona
  • • Centennial, Colorado
  • • Plymouth, Minnesota
  • • And 2 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID) - Join Clinical Trial NCTNCT07076446

How to Join This Clinical Trial - NCTNCT07076446

Learn how to participate in this PHASE4 trial studying an investigational therapy for Primary Immunodeficiency. This study is currently enrolling participants.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Primary Immunodeficiency. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Primary Immunodeficiency
Treatment Being Tested
Investigational treatment
Study Phase
PHASE4 - Research study
Enrollment Status
Currently enrolling participants
Study Identifier
NCTNCT07076446 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 5 locations. Find a study site near you:

Clinical Research Site

Litchfield Park, Arizona 85340 - United States

Status: RECRUITING

Clinical Research Site

Centennial, Colorado 80112 - United States

Status: RECRUITING

Clinical Research Site

Plymouth, Minnesota 55446 - United States

Status: RECRUITING

Clinical Research Site

Oklahoma City, Oklahoma 73120 - United States

Status: RECRUITING

Clinical Research Site

Pittsburgh, Pennsylvania 15241 - United States

Status: RECRUITING

How to Enroll in This Study

To learn more about participating in this PHASE4 clinical trial for Primary Immunodeficiency:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships